

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)



(10) International Publication Number
WO 2023/122140 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) C07D 519/00 (2006.01)
C07D 471/04 (2006.01) A61K 31/435 (2006.01)
C07D 487/04 (2006.01) A61K 31/4375 (2006.01)
C07D 491/052 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/053591

(22) International Filing Date:

21 December 2022 (21.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/292,903 22 December 2021 (22.12.2021) US
63/327,228 04 April 2022 (04.04.2022) US
63/403,459 02 September 2022 (02.09.2022) US

(71) Applicant: SYNNOVATION THERAPEUTICS, INC.

[US/US]; 200 Powder Mill Road E500-1801, Wilmington,
Delaware 19803 (US).

(72) Inventors: PAN, Jun; c/o Synnovation Therapeutics, Inc.,

200 Powder Mill Road E500, Wilmington, Delaware 19803
(US). BAI, Yu; c/o Synnovation Therapeutics, Inc., 200
Powder Mill Road E500, Wilmington, Delaware 19803
(US). ZHENG, Hewen; c/o Synnovation Therapeutics,
Inc., 200 Powder Mill Road E500, Wilmington, Delaware
19803 (US). LI, Yu; c/o Synnovation Therapeutics, Inc.,
200 Powder Mill Road E500, Wilmington, Delaware 19803
(US). YANG, Jeffrey; c/o Synnovation Therapeutics, Inc.,
200 Powder Mill Road E500, Wilmington, Delaware 19803
(US). WU, Liangxing; c/o Synnovation Therapeutics, Inc.,
200 Powder Mill Road E500, Wilmington, Delaware 19803
(US). YAO, Wenqing; c/o Synnovation Therapeutics, Inc.,
200 Powder Mill Road E500, Wilmington, Delaware 19803
(US).

(74) Agent: GODDARD, PH.D., Christine A. et al.; Fish &

Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota
55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PARP1 INHIBITORS

(57) Abstract: The present disclosure provides compounds, compositions, and methods useful for inhibiting PARP1, and/or treating a disease, disorder, or condition associated with PARP1, and/or treating cancer.

WO 2023/122140 A1